Medicare GLP-1 Bridge Program Explained: Who Qualifies, What It Costs, and How to Get It

We built this guide to be the only page you need. Whether you qualify for the Bridge, need to use regular Part D, or want alternatives while you wait — we'll walk you through every path and every decision, step by step.

What Is the Medicare GLP-1 Bridge Program?

The Medicare GLP-1 Bridge is a temporary demonstration program run by the Centers for Medicare & Medicaid Services (CMS). It provides eligible Medicare Part D beneficiaries with access to FDA-approved GLP-1 weight loss medications at a $50 monthly copay.

Here's the essential context: federal law has prohibited Medicare from covering medications prescribed solely for weight loss since 2003. That means for over two decades, Medicare generally did not cover GLP-1s when prescribed only for weight loss — so beneficiaries who wanted Wegovy or Zepbound for weight management alone usually needed a cash-pay path outside of Medicare. At list prices above $1,000 per month, that put treatment out of reach for most people on a fixed income.

The Bridge changes that — temporarily.

CMS announced the program on December 23, 2025, and released the detailed FAQ on March 3, 2026. It uses a special legal authority (Section 402 of the Social Security Amendments) to operate outside the normal Part D system. That's important because it means:

• Your Part D plan does not need to “opt in.” The Bridge is administered directly by CMS through a central processor.
• Your Part D plan is not directly involved in Bridge claims or payment. Bridge prior authorizations go to CMS's central processor, not your plan. Standard Part D coverage decisions still go through your plan as usual.
• Pharmacies do not need to opt in to the Bridge. CMS is still issuing operational guidance, but pharmacies are not required to enroll separately.

The Bridge runs from July 1 through December 31, 2026 — six months, not a day longer. After that, continued Medicare coverage for weight-loss GLP-1s depends on the BALANCE Model launching in Medicare for 2027 and your enrollment in a participating Part D plan. That transition is not automatic — we'll explain exactly why it matters later.

Do You Qualify for the Medicare GLP-1 Bridge?

CMS published specific eligibility criteria in the March 2026 FAQ, and they're more detailed than most news articles let on. There are three distinct tiers, and you only need to meet one of them — plus baseline requirements that apply to everyone.

Requirements That Apply to Everyone

• Enrolled in Medicare Part D for 2026 — either a standalone Prescription Drug Plan (PDP) or a Medicare Advantage plan with drug coverage (MA-PD).
• Special Needs Plans (SNPs), employer/union group waiver plans (EGWPs), and LI NET are all eligible.
• Not eligible: private fee-for-service plans, Section 1876 cost contract plans, Section 1833 health care prepayment plans, PACE organizations, fallback plans, and religious fraternal benefit plans — unless you're also enrolled in a standalone PDP.
• Dual-eligible beneficiaries (enrolled in both Medicare and Medicaid) can qualify if they're in an eligible Part D plan type.
• The medication must be prescribed for weight loss — specifically, “to reduce excess body weight and maintain weight reduction in combination with current and ongoing lifestyle modification including structured nutrition and physical activity.”

Tier 1: BMI of 35 or Higher

This is the simplest path. If your Body Mass Index is 35 or above at the time you start GLP-1 therapy, you qualify with no additional diagnosis required.

For reference: a person who is 5'6“ and weighs 217 pounds has a BMI of approximately 35. A person who is 5'10“ and weighs 244 pounds has a BMI of approximately 35. Your doctor attests to your BMI and confirms you're committed to ongoing lifestyle modification. That's it.

Tier 2: BMI of 30 or Higher + Specific Heart or Kidney Conditions

If your BMI is 30 or above but below 35, you can qualify if you also have one or more of the following:

• Heart failure with preserved ejection fraction (HFpEF)
• Uncontrolled hypertension — defined as systolic BP above 140 mm Hg or diastolic above 90 mm Hg while on two or more antihypertensive medications
• Chronic kidney disease (CKD) stage 3a or above

Tier 3: BMI of 27 or Higher + Specific Cardiovascular or Metabolic Conditions

If your BMI is 27 or above but below 30, you can qualify if you have one or more of the following:

• Prediabetes (as defined by American Diabetes Association guidelines)
• Previous myocardial infarction (heart attack)
• Previous stroke
• Symptomatic peripheral artery disease

Quick BMI Reference

BMI is measured at the time of initiating GLP-1 therapy, not at your all-time highest weight.

What GLP-1 Medications Are Covered Under the Bridge?

This is simpler than you might expect — and also more limited.

Covered Under the Bridge

That's the complete list. Three products, two active ingredients, all FDA-approved specifically for weight loss.

NOT Covered Under the Bridge

The Ozempic Question

We know this comes up constantly: “Ozempic and Wegovy are the same active ingredient — can I get Ozempic through the Bridge?” No. Despite containing the same active ingredient (semaglutide), Ozempic and Wegovy are different FDA-approved products with different approved indications. Ozempic is approved for type 2 diabetes. Wegovy is approved for weight management. The Bridge only covers medications prescribed for weight loss, and only covers the specific products listed above.

The Indication Matters More Than the Drug Name

Here's something most articles miss: the same medication can be covered through different pathways depending on why it's prescribed.

• Wegovy for weight loss → Medicare GLP-1 Bridge (July–December 2026)
• Wegovy for cardiovascular risk reduction in adults with established CV disease → regular Medicare Part D (if your plan covers it)
• Zepbound for weight loss → Medicare GLP-1 Bridge
• Zepbound for obstructive sleep apnea in adults with obesity → regular Medicare Part D (if your plan covers it)

How Much Does the Medicare GLP-1 Bridge Really Cost?

The headline number is $50 per month. Eligible beneficiaries pay a flat $50 copay at the pharmacy, regardless of the medication or dose — no tiered pricing, no coinsurance percentage, no deductible to meet first.

But the financial picture is more nuanced than one number.

How to Get the Medicare GLP-1 Bridge: Step by Step

The Bridge doesn't work like a normal Part D prescription. Your insurance company isn't involved. There's a different process, and understanding it now — before July — puts you ahead of what will likely be a flood of applicants on launch day.

What Happens After December 2026? The Transition You Need to Plan For

The Bridge ends December 31, 2026. There is no extension, no grace period, and no automatic continuation.

If you start Wegovy or Zepbound through the Bridge in July and want to continue past December, you'll need to be enrolled in a Part D plan that participates in the BALANCE Model — CMS's longer-term program that launches for Medicare Part D plans on January 1, 2027.

The BALANCE Model Is Voluntary

What the BALANCE Model Changes in 2027

• How it works: Unlike the Bridge (where CMS handles everything directly), BALANCE operates through your Part D plan. Your plan processes claims, manages prior authorization, and handles your prescription like any other Part D drug.
• What it covers: A significantly broader drug list than the Bridge — including Wegovy, Zepbound, Ozempic, Mounjaro, Rybelsus, and others pending FDA approval.
• The cost structure: Not a simple flat-$50 program. Beneficiary cost sharing varies by plan type and benefit phase — some plans cap initial-coverage cost sharing at $50, others at $125; catastrophic phase is $0. Crucially: whatever you pay under BALANCE does count toward your Part D deductible and out-of-pocket cap.
• The lifestyle component: All beneficiaries receiving GLP-1s through BALANCE will have access to a manufacturer-provided lifestyle support program at no additional cost.

Why Stopping a GLP-1 Matters Medically

This isn't just a paperwork issue. In the STEP 1 extension study, participants who stopped semaglutide regained about two-thirds of prior weight loss within one year. GLP-1 medications work while you're taking them. The benefits don't persist once you stop. Starting a GLP-1 in July with no plan for January isn't necessarily the wrong move — six months of treatment can deliver meaningful health improvements — but go in with eyes open and a transition plan in place.

Your December Cliff Checklist

The beneficiaries who maintain their progress will be the ones who plan ahead — not the ones who scramble in December.

Medicare GLP-1 Bridge vs. Standard Part D vs. BALANCE Model

One of the biggest sources of confusion right now is the relationship between three overlapping Medicare GLP-1 pathways. They are not the same thing, and confusing them could cost you time, money, or both.

Which Lane Are You In?

• Weight loss only: The Bridge (July–Dec. 2026), then BALANCE (2027+), is your path. Neither regular Part D nor current law can cover this.
• Type 2 diabetes: Your regular Part D plan may already cover Ozempic, Mounjaro, or Rybelsus. Check your plan's formulary. You do NOT need the Bridge.
• Cardiovascular disease and overweight or obese: Wegovy is FDA-approved for cardiovascular risk reduction. Your Part D plan may cover it for this indication, which is a better deal than the Bridge because Part D payments count toward your out-of-pocket cap and Extra Help applies.
• Obstructive sleep apnea and obesity: Zepbound is FDA-approved for moderate to severe OSA. Same logic — Part D coverage for the sleep apnea indication may be a better financial deal.

Biggest Misunderstandings About the $50 Medicare GLP-1 Program

We've read every major article, official FAQ, and forum thread about this program. These are the most common misunderstandings — each one can lead to wasted time or wrong decisions.

What Medicare Already Covers Without the Bridge

Before you pursue the Bridge, it's worth checking whether you already have a GLP-1 coverage pathway you might not know about. Many Medicare beneficiaries do — and the regular Part D pathway can actually be better than the Bridge because it counts toward your out-of-pocket cap and Extra Help applies.

What Beneficiaries Are Actually Asking Right Now

We monitor forums, Medicare communities, and reader questions to understand what real beneficiaries are confused about. Here are the themes that keep coming up.

What If You Don't Qualify for the Medicare GLP-1 Bridge?

Not everyone will qualify — and that's the reality we need to address honestly. Maybe your BMI doesn't meet the thresholds. Maybe you're in a plan type that's excluded. Maybe you don't have one of the specific qualifying conditions. Or maybe you just don't want to wait until July. Whatever the reason, you are not out of options.

Option 1: Check Whether Regular Part D Already Covers Your GLP-1

If you have type 2 diabetes, cardiovascular disease, or obstructive sleep apnea, your Part D plan may already cover a GLP-1 for that condition. This is the first thing to check because it costs you nothing to investigate and uses the coverage you're already paying for. Call the number on the back of your Part D card and ask: “Does my plan cover [Ozempic / Wegovy / Zepbound] for [your condition]? What's the prior authorization process?”

Option 2: FDA-Approved GLP-1 Through a Telehealth Provider

If regular Part D doesn't apply and the Bridge doesn't either, you can still access FDA-approved Wegovy and Zepbound through telehealth medical programs — without waiting for any government program to launch.

Ro is the most comprehensive option we've evaluated for this. Their Body program pairs you with a licensed physician who evaluates your health, prescribes FDA-approved GLP-1 medication if appropriate, and provides ongoing clinical support including dose management and side-effect guidance. The membership starts at $45 for the first month and $145/month after that, with medication billed separately. Cash-pay medication options start at $149/month for lower doses.

What makes Ro worth highlighting here: it's month-to-month with no long-term contract, so you can start now and transition to Bridge or BALANCE coverage later without penalty. It also serves as a smart insurance policy — if BALANCE doesn't materialize in 2027 or your plan doesn't participate, you already have a clinical relationship and treatment plan in place.

Option 3: Compounded GLP-1 Programs

For beneficiaries on tighter budgets where brand-name medication pricing isn't feasible, compounded GLP-1 programs offer a lower entry point.

We want to be clear about what this means: compounded GLP-1 products are not FDA-approved finished drugs. The FDA does not review them for safety, effectiveness, or quality before they are marketed, and the agency has raised concerns about dosing inconsistencies and misleading promotional claims in this category. This is not the same as saying they are dangerous — but you should understand the distinction before deciding.

MEDVi is the strongest option we've evaluated in this category. They offer compounded semaglutide and tirzepatide starting at $179 per month with no membership fees, no contracts, and month-to-month billing. Treatment is overseen by licensed physicians, and medications ship from licensed U.S. compounding pharmacies.

Option 4: TrumpRx Self-Pay Pricing

TrumpRx.gov is a government-backed platform offering reduced self-pay prices on brand-name GLP-1 medications. Check TrumpRx.gov directly for current figures, as they update periodically. Note that patients covered by government insurance programs like Medicare and Medicaid may face eligibility restrictions on certain discount programs offered through the platform.

Choosing Your Path

Can't Wait Until July? How to Start GLP-1 Treatment Now

The Bridge doesn't open until July 1, 2026. If you've been thinking about GLP-1 treatment — if you've watched the news coverage, talked to friends who've had success, or discussed it with your doctor — you don't have to wait three more months to begin.

Many people use the months before July to start their GLP-1 journey, build the habit, manage initial side effects (which are often most noticeable in the first few weeks), and get to a stable dose. By the time Bridge coverage kicks in, they're already seeing results and can transition their coverage to $50/month.

Why Starting Early Is Medically Smart

GLP-1 medications use a dose titration schedule. You don't start at the full dose. Wegovy begins at 0.25 mg weekly and gradually increases over about 16–20 weeks to reach the maintenance dose of 2.4 mg. Zepbound starts at 2.5 mg and titrates up to 15 mg over a similar period. During those early weeks, side effects like nausea, constipation, or decreased appetite are most common. Most patients find they diminish significantly as the body adjusts. If you start in April or May, you'll be through the toughest adjustment period before the Bridge even launches.

Here's What the Timeline Looks Like

The Financial Math of Starting Early

Yes, you'll pay more per month before July. But consider: three months of waiting is three months of not losing weight, not improving your health markers, and then scrambling to start from scratch while everyone else floods the prior authorization system at once. For many people, the health improvements in those first three months — lower blood pressure, better blood sugar, reduced inflammation, improved mobility — are worth the investment even before Bridge pricing kicks in.

What These Medications Actually Do

The Bridge hasn't launched yet, so there are no Bridge-specific patient outcomes to report. But the medications it covers — Wegovy and Zepbound — have been studied extensively, and the clinical evidence is strong.

• In the pivotal STEP trials, patients taking semaglutide (the active ingredient in Wegovy) lost an average of approximately 15% of their body weight over 68 weeks when combined with diet and exercise, compared to about 2.4% with diet and exercise alone.
• In trials of tirzepatide (the active ingredient in Zepbound), patients lost an average of approximately 18–21% of body weight depending on the dose, compared to about 3% with placebo.
• For someone weighing 250 pounds, that translates to roughly 37 to 52 pounds of weight loss.
• The SELECT cardiovascular outcomes trial demonstrated that semaglutide reduced the risk of major adverse cardiovascular events by 20% in adults with established heart disease and overweight or obesity.

These aren't miracle drugs. They work best alongside real changes in nutrition and physical activity. Side effects — particularly gastrointestinal symptoms — are common, especially during dose titration, and not everyone responds the same way. But for people who have struggled with weight for years despite genuine effort, GLP-1 medications represent the most effective pharmacological tool available. The Bridge makes them accessible to Medicare beneficiaries at a price point that was unthinkable even a year ago.

Frequently Asked Questions

Our Sources and How We Keep This Updated

Every eligibility criterion, every cost figure, every program date on this page was verified against official CMS documentation. We don't rely on secondary reporting for core facts.

What we verified ourselves:

• The three distinct BMI/diagnosis eligibility tiers — and the fact that many other sites compress or misstate them
• That SNP, EGWP, and LI NET beneficiaries ARE eligible (contrary to at least one major competing article)
• That Part D plans do NOT need to opt in for the Bridge (contrary to at least two competing articles)
• The exact covered products: Wegovy injection, Wegovy oral tablet, and Zepbound only
• The $50 copay structure and its exclusion from Part D TrOOP and deductible calculations
• The BIN (028918) and PCN (MEDDGLP1BR) for pharmacy claims processing
• The net manufacturer price of $245 per monthly supply
• The July 1 – December 31, 2026 program dates

Primary sources:

• CMS Medicare GLP-1 Bridge FAQ page — last verified March 25, 2026
• CMS BALANCE Model overview
• CMS press release, December 23, 2025
• KFF analysis of the Bridge and BALANCE Model
• FDA compounding enforcement guidance
• STEP 1 extension study (semaglutide weight regain)

This page is updated whenever CMS releases new guidance about the Bridge or BALANCE Model. Key dates to watch: Spring 2026 (additional CMS details on prior authorization process), July 1, 2026 (Bridge launch), and October–December 2026 (BALANCE participation announcements and open enrollment decisions).

Still Not Sure Which GLP-1 Program Is Right for You?

The Medicare GLP-1 Bridge is a big deal — the first time in over 20 years that Medicare beneficiaries can access weight-loss medications at an affordable price. But it's not the only path, and it's not the right fit for everyone.

Whether you qualify for the Bridge, need to use regular Part D for a covered indication, want to plan for BALANCE in 2027, or need a telehealth option that starts today — the right program depends on your BMI, your health conditions, your budget, and your timeline.